Oxcarbazepine Tablet, Film Coated
Product Images NDC 0904-7264

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 0904-7264). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (B1d54def 057d 4608 Bc8f 1d967ac3ec91 00)

Label for OXCARBAZEPINE Tablets, USP 600 mg film-coated tablets by Major Pharmaceuticals. The label includes the NDC number 0904-7264-61 and indicates the product is for oral use, prescription only, with 100 tablets per unit dose. It advises pharmacists to dispense with a medication guide and includes storage instructions and manufacturer details.*

FDA Label Image

Carton Label (B1d54def 057d 4608 Bc8f 1d967ac3ec91 01)

Label for Oxcarbazepine Tablets USP, 300 mg film-coated oral tablets by Major Pharmaceuticals. The label includes NDC 0904-7263-61, specifies a unit dose package of 100 tablets, and instructions to dispense with the medication guide. It notes the presence of FD&C Yellow No. 5 as a color additive and provides storage conditions and dosage instructions referencing the product insert.*

FDA Label Image

Carton Label (B1d54def 057d 4608 Bc8f 1d967ac3ec91 02)

Packaging label for OXCARBAZEPINE 150 mg tablets, USP, film-coated oral tablets, supplied by Major Pharmaceuticals. The label states the dosage strength as 150 mg and indicates a package size of 100 tablets. It includes dispensing instructions to pharmacists and storage conditions, as well as manufacturer and distributor information.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine, displaying the molecular arrangement including two benzene rings fused to a central ring with a keto group and a CONH2 side chain.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier chart showing exit rates over time on trial from day 2 to day 11, comparing treatment groups of Oxcarbazepine and Placebo. The x-axis is labeled with days and times, and the y-axis represents the exit rate. Oxcarbazepine treatment shows a lower exit rate than placebo, with a log-rank test p-value of 0.0001 indicated on the chart.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve chart depicting seizure rate over days from first dose to first seizure in two treatment groups: Oxcarbazepine and Placebo. The X-axis shows days from 0 to 140, and the Y-axis shows seizure rate from 0.0 to 1.0. The chart includes a log-rank test p-value of 0.046.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A Kaplan-Meier plot showing time to exit in days on the x-axis and exit rate on the y-axis, comparing two treatment groups labeled HIGH and LOW. The HIGH group is represented by a solid line and the LOW group by a dashed line. The plot includes a log-rank test p-value of 0.0001, indicating statistical comparison between the groups.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

Kaplan-Meier curve displaying exit rates over time (days) comparing two treatment groups, HIGH and LOW, for Oxcarbazepine. The x-axis shows time to exit in days, and the y-axis represents the exit rate. A log-rank test p-value of 0.0001 is indicated, suggesting statistically significant differences between groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.